RxDoctor Payments Data

Sherri Szczepanski

Family · Green Bay, WINPI 1649292772

Payments from drug & device makers

$1,137in general payments, 2019–2025

Across 11 payments — averaging $103.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$464
  • Boehringer Ingelheim$125
  • BETA Bionics, Inc.$117
  • Madrigal Pharmaceuticals$114
  • Medtronic$90
  • Lilly USA, LLC$86
  • plus $141 from 4 others

What the payments were for

  • Food & beverage$67359%
  • Education$46441%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,137 in reported general payments places this provider in the 85th percentile of 1,273 family providers in Wisconsin.

See all family providers in Wisconsin

Medicare billing

Part B allowed, 2024
$56,967
Medicare patients
135
Services billed
1,061

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide257$353,922
MounjaroTirzepatide207$285,104
TrulicityDulaglutide184$219,559
JardianceEmpagliflozin173$163,977
RybelsusSemaglutide79$88,902
Tresiba Flextouch U-100Insulin Degludec81$78,082
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog109$78,054
Tresiba Flextouch U-200Insulin Degludec45$77,157
Humalog Kwikpen U-100Insulin Lispro213$76,480
Lantus SolostarInsulin Glargine,hum.Rec.Anlog423$65,450
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/760$59,073
TradjentaLinagliptin69$56,184
Humulin R U-500 KwikpenInsulin Regular, Human24$47,423
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$46,668
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog87$37,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$86$520,826495 claims
Novo NordiskOzempic, Rybelsus, Novolog$464$451,934366 claims
Boehringer IngelheimJardiance, Tradjenta$125$220,161242 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,273 family providers in Wisconsin.

Other family in Green Bay

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →